CY1124302T1 - Ισοκινολιν-3-υλο καρβοξαμιδια και παρασκευη και χρηση αυτων - Google Patents
Ισοκινολιν-3-υλο καρβοξαμιδια και παρασκευη και χρηση αυτωνInfo
- Publication number
- CY1124302T1 CY1124302T1 CY20211100344T CY211100344T CY1124302T1 CY 1124302 T1 CY1124302 T1 CY 1124302T1 CY 20211100344 T CY20211100344 T CY 20211100344T CY 211100344 T CY211100344 T CY 211100344T CY 1124302 T1 CY1124302 T1 CY 1124302T1
- Authority
- CY
- Cyprus
- Prior art keywords
- disorders
- wnt
- wnt signaling
- diseases
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Αποκαλύπτονται ενώσεις ισοκινολίνης για τη θεραπευτική αντιμετώπιση διαφόρων ασθενειών και παθολογιών. Πιο συγκεκριμένα, η παρούσα εφεύρεση αφορά στη χρήση μιας ένωσης ισοκινολίνης ή αναλόγων αυτής, στην αγωγή διαταραχών που χαρακτηρίζονται από την ενεργοποίηση του σηματοδοτικού μονοπατιού Wnt (π.χ., καρκίνος, μη φυσιολογικός πολλαπλασιασμός κυττάρων, αγγειογένεση, ινωτικές διαταραχές, ασθένειες οστού ή χόνδρου, και οστεοαρθρίτιδα}, τη διαμόρφωση κυτταρικών συμβάντων διά της μεσολάβησης του σηματοδοτικού μονοπατιού Wnt, καθώς και γενετικών παθήσεων και νευρολογικών καταστάσεων/διαταραχών/ασθενειών που οφείλονται σε μεταλλάξεις ή στη δυσλειτουργία του μονοπατιού Wnt ή/και ενός ή περισσότερων συστατικών σηματοδότησης Wnt. Παρέχονται επίσης μέθοδοι για τη θεραπευτική αντιμετώπιση καταστάσεων ασθένειας που σχετίζονται με το Wnt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662328255P | 2016-04-27 | 2016-04-27 | |
| PCT/US2017/029805 WO2017189829A1 (en) | 2016-04-27 | 2017-04-27 | Isoquinolin-3-yl carboxamides and preparation and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124302T1 true CY1124302T1 (el) | 2022-07-22 |
Family
ID=60157337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100344T CY1124302T1 (el) | 2016-04-27 | 2021-04-21 | Ισοκινολιν-3-υλο καρβοξαμιδια και παρασκευη και χρηση αυτων |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US10106527B2 (el) |
| EP (2) | EP3448386B1 (el) |
| JP (1) | JP6993985B2 (el) |
| KR (1) | KR102374844B1 (el) |
| CN (1) | CN109310690B (el) |
| AR (1) | AR108325A1 (el) |
| AU (1) | AU2017258193B2 (el) |
| CA (1) | CA3022002A1 (el) |
| CL (2) | CL2018003065A1 (el) |
| CO (1) | CO2018012299A2 (el) |
| CY (1) | CY1124302T1 (el) |
| DK (1) | DK3448386T3 (el) |
| ES (1) | ES2865374T3 (el) |
| HR (1) | HRP20210607T1 (el) |
| HU (1) | HUE054103T2 (el) |
| IL (1) | IL262470B (el) |
| LT (1) | LT3448386T (el) |
| MA (1) | MA43619B1 (el) |
| MD (1) | MD3448386T2 (el) |
| MX (1) | MX2018013174A (el) |
| MY (1) | MY198966A (el) |
| PE (1) | PE20190326A1 (el) |
| PH (1) | PH12018502258A1 (el) |
| PL (1) | PL3448386T3 (el) |
| PT (1) | PT3448386T (el) |
| RS (1) | RS61879B1 (el) |
| SG (2) | SG10201914054SA (el) |
| SI (1) | SI3448386T1 (el) |
| SM (1) | SMT202100224T1 (el) |
| WO (1) | WO2017189829A1 (el) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| US10544139B2 (en) | 2015-11-06 | 2020-01-28 | Samumed, Llc | Treatment of osteoarthritis |
| US10874672B2 (en) | 2015-12-10 | 2020-12-29 | Ptc Therapeutics, Inc. | Methods for treating Huntington's disease |
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| TW201803869A (zh) | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑 |
| US10072004B2 (en) | 2016-06-01 | 2018-09-11 | Samumed, Llc | Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo [4,5-C]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide |
| RU2019133646A (ru) | 2017-03-30 | 2021-04-30 | Ф. Хоффманн-Ля Рош Аг | Изохинолины в качестве ингибиторов hpk1 |
| KR20200033249A (ko) | 2017-06-05 | 2020-03-27 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| CA3067592A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
| US10604514B2 (en) | 2017-10-19 | 2020-03-31 | Samumed, Llc | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof |
| US10413537B2 (en) | 2017-10-27 | 2019-09-17 | Samumed, Llc | 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof |
| WO2019084497A1 (en) | 2017-10-27 | 2019-05-02 | Samumed, Llc | 6- (HETEROARYL AND ARYL WITH 6 CHAINS) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE |
| WO2019089835A1 (en) * | 2017-10-31 | 2019-05-09 | Samumed, Llc | Diazanaphthalen-3-yl carboxamides and preparation and use thereof |
| CA3094703A1 (en) | 2018-03-27 | 2019-10-03 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| EP3790865A1 (en) | 2018-06-18 | 2021-03-17 | Janssen Pharmaceutica NV | Phenyl substituted pyrazoles as modulators of roryt |
| ES2928246T3 (es) | 2018-06-18 | 2022-11-16 | Janssen Pharmaceutica Nv | 6-aminopiridin-3-il pirazoles como moduladores de RORyt |
| JP2021527660A (ja) | 2018-06-18 | 2021-10-14 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲγｔのモジュレータとしてのフェニル及びピリジニル置換イミダゾール |
| US11034658B2 (en) | 2018-06-18 | 2021-06-15 | Janssen Pharmaceutica Nv | Pyridinyl pyrazoles as modulators of RORγT |
| WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| SG11202012674PA (en) | 2018-06-27 | 2021-01-28 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for treating huntington's disease |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| EP3911317A2 (en) | 2019-01-17 | 2021-11-24 | BioSplice Therapeutics, Inc. | Methods of treating cartilage disorders through inhibition of clk and dyrk |
| WO2021004547A1 (en) * | 2019-07-11 | 2021-01-14 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of hpk1 |
| WO2021007378A1 (en) * | 2019-07-11 | 2021-01-14 | Ptc Therapeutics, Inc. | Compounds for use in treating huntington's disease |
| EP4154886A4 (en) * | 2020-05-20 | 2023-11-08 | Osaka University | Cug repeat sequence binding agent |
| CN117088877A (zh) * | 2020-10-28 | 2023-11-21 | 杭州阿诺生物医药科技有限公司 | 一种高活性Wnt通路抑制剂化合物 |
| EP4244213A4 (en) * | 2020-11-10 | 2024-11-20 | Foghorn Therapeutics Inc. | COMPOUNDS AND USES THEREOF |
| TW202321244A (zh) * | 2021-07-26 | 2023-06-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Ｗｎｔ通路抑制劑化合物 |
| TW202334157A (zh) * | 2022-01-29 | 2023-09-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Ｗｎｔ通路抑制劑化合物 |
| WO2024022365A1 (zh) * | 2022-07-28 | 2024-02-01 | 杭州阿诺生物医药科技有限公司 | 一种Wnt通路抑制剂化合物 |
| WO2024238620A1 (en) * | 2023-05-17 | 2024-11-21 | Woolsey Pharmaceuticals, Inc. | Methods of treating traumatic encephalopathy syndrome |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
| US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| DE19746287A1 (de) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US6440102B1 (en) | 1998-07-23 | 2002-08-27 | Durect Corporation | Fluid transfer and diagnostic system for treating the inner ear |
| DE19853299C2 (de) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs |
| US6120484A (en) | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
| US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| US6648873B2 (en) | 2001-09-21 | 2003-11-18 | Durect Corp. | Aural catheter system including anchor balloon and balloon inflation device |
| GB0310867D0 (en) * | 2003-05-12 | 2003-06-18 | Novartis Ag | Organic compounds |
| MXPA06000794A (es) | 2003-07-22 | 2006-08-23 | Astex Therapeutics Ltd | Compuestos 1h-pirazola 3,4-disustituida y su uso como moduladores de quinasas dependientes de ciclina (cdk) y quinasa-3 de sintasa de glicogeno (gsr-3). |
| US7008953B2 (en) | 2003-07-30 | 2006-03-07 | Agouron Pharmaceuticals, Inc. | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| WO2006079055A2 (en) | 2005-01-24 | 2006-07-27 | Neurosystec Corporation | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues |
| US7998978B2 (en) | 2006-05-01 | 2011-08-16 | Pfizer Inc. | Substituted 2-amino-fused heterocyclic compounds |
| US8088793B2 (en) | 2007-08-15 | 2012-01-03 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| WO2009085226A2 (en) | 2007-12-21 | 2009-07-09 | Sirtris Pharmaceuticals, Inc. | Inhibitors of cdc2-like kinases (clks) and methods of use thereof |
| UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| CA2770320A1 (en) | 2009-08-10 | 2011-02-17 | Epitherix, Llc | Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof |
| DK2987487T3 (da) | 2009-08-10 | 2020-12-07 | Samumed Llc | Indazolinhibitorer af wnt-signalvejen og terapeutiske anvendelser deraf |
| US7998878B2 (en) | 2009-11-20 | 2011-08-16 | Eastman Kodak Company | Method for selective deposition and devices |
| EP3305073B1 (en) | 2009-12-21 | 2019-05-15 | Samumed, LLC | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| EP2552893B1 (en) | 2010-03-31 | 2014-10-29 | Actelion Pharmaceuticals Ltd. | Antibacterial isoquinolin-3-ylurea derivatives |
| BR112013013790A2 (pt) | 2010-12-17 | 2016-09-13 | Hoffmann La Roche | compostos heterocíclos nitrogenosos 6,6-fundidos substituídos e usos dos mesmos |
| CN102558173B (zh) * | 2010-12-31 | 2015-05-20 | 广州源生医药科技有限公司 | 抑制wnt信号传导的化合物、组合物及其应用 |
| PE20141678A1 (es) | 2011-09-14 | 2014-11-21 | Samumed Llc | Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina |
| WO2013169793A2 (en) * | 2012-05-09 | 2013-11-14 | Ipierian, Inc. | Methods and compositions for tdp-43 proteinopathies |
| US9557993B2 (en) | 2012-10-23 | 2017-01-31 | Analog Devices Global | Processor architecture and method for simplifying programming single instruction, multiple data within a register |
| SG11201607816UA (en) | 2014-03-20 | 2016-10-28 | Samumed Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| EP3518925A4 (en) | 2016-09-30 | 2020-04-15 | SRI International | Dual clk/cdk1 inhibitors for cancer treatment |
| US20220062240A1 (en) | 2018-06-26 | 2022-03-03 | Biosplice Therapeutics, Inc. | Methods of treating cancer using a clk inhibitor |
| WO2020150545A1 (en) | 2019-01-17 | 2020-07-23 | Samumed, Llc | Pyrazole derivatives as modulators of the wnt/b-catenin signaling pathway |
-
2017
- 2017-04-26 AR ARP170101055A patent/AR108325A1/es unknown
- 2017-04-27 EP EP17790416.6A patent/EP3448386B1/en active Active
- 2017-04-27 CA CA3022002A patent/CA3022002A1/en active Pending
- 2017-04-27 WO PCT/US2017/029805 patent/WO2017189829A1/en active Application Filing
- 2017-04-27 AU AU2017258193A patent/AU2017258193B2/en active Active
- 2017-04-27 MA MA43619A patent/MA43619B1/fr unknown
- 2017-04-27 EP EP21159576.4A patent/EP3892276A1/en active Pending
- 2017-04-27 MX MX2018013174A patent/MX2018013174A/es unknown
- 2017-04-27 SI SI201730725T patent/SI3448386T1/sl unknown
- 2017-04-27 KR KR1020187034084A patent/KR102374844B1/ko active Active
- 2017-04-27 DK DK17790416.6T patent/DK3448386T3/da active
- 2017-04-27 MY MYPI2018001772A patent/MY198966A/en unknown
- 2017-04-27 PL PL17790416T patent/PL3448386T3/pl unknown
- 2017-04-27 MD MDE20190282T patent/MD3448386T2/ro unknown
- 2017-04-27 SG SG10201914054SA patent/SG10201914054SA/en unknown
- 2017-04-27 RS RS20210466A patent/RS61879B1/sr unknown
- 2017-04-27 LT LTEP17790416.6T patent/LT3448386T/lt unknown
- 2017-04-27 SG SG11201809301YA patent/SG11201809301YA/en unknown
- 2017-04-27 CN CN201780037225.6A patent/CN109310690B/zh active Active
- 2017-04-27 SM SM20210224T patent/SMT202100224T1/it unknown
- 2017-04-27 ES ES17790416T patent/ES2865374T3/es active Active
- 2017-04-27 US US15/499,013 patent/US10106527B2/en active Active
- 2017-04-27 PT PT177904166T patent/PT3448386T/pt unknown
- 2017-04-27 JP JP2018556902A patent/JP6993985B2/ja active Active
- 2017-04-27 PE PE2018002194A patent/PE20190326A1/es unknown
- 2017-04-27 HU HUE17790416A patent/HUE054103T2/hu unknown
- 2017-12-06 US US15/833,917 patent/US9951048B1/en active Active
-
2018
- 2018-01-30 US US15/884,112 patent/US10100038B2/en active Active
- 2018-09-13 US US16/130,842 patent/US10544128B2/en active Active
- 2018-10-18 IL IL262470A patent/IL262470B/en unknown
- 2018-10-23 PH PH12018502258A patent/PH12018502258A1/en unknown
- 2018-10-26 CL CL2018003065A patent/CL2018003065A1/es unknown
- 2018-11-14 CO CONC2018/0012299A patent/CO2018012299A2/es unknown
-
2019
- 2019-05-16 CL CL2019001343A patent/CL2019001343A1/es unknown
- 2019-12-04 US US16/703,321 patent/US10947217B2/en active Active
-
2021
- 2021-01-22 US US17/155,577 patent/US11548872B2/en active Active
- 2021-04-16 HR HRP20210607TT patent/HRP20210607T1/hr unknown
- 2021-04-21 CY CY20211100344T patent/CY1124302T1/el unknown
-
2022
- 2022-11-18 US US17/990,133 patent/US20230286945A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124302T1 (el) | Ισοκινολιν-3-υλο καρβοξαμιδια και παρασκευη και χρηση αυτων | |
| CY1122795T1 (el) | Ινδαζολο-3-καρβοξαμιδια και η χρηση τους ως αναστολεις του σηματοδοτικου μονοπατιου wnt/b-κατενινης | |
| CY1119485T1 (el) | Αναστολεις ινδαζολης του σηματοδοτικου μονοπατιου wnt και θεραπευτικες χρησεις αυτων | |
| CO2018012655A2 (es) | Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas | |
| PH12016501835A1 (en) | 5-substituted indazole -3- carboxamides and preparation and use thereof | |
| EA201590850A1 (ru) | Трициклические конденсированные производные тиофена как ингибиторы jak | |
| CL2019003419A1 (es) | Polipéptidos que antagonizan la señalización wnt en células tumorales. | |
| EA201990912A1 (ru) | Анти-lag-3 антитела и их композиции | |
| EA201990187A1 (ru) | Антипролиферационные средства на основе пиримидина | |
| MX370487B (es) | Inhibidores de 3-(benzo-imidazol-2-il)-indazol de la senda de señalización de wnt y usos terapéuticos de los mismos. | |
| EA201691940A1 (ru) | Новые соединения | |
| CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
| EA201591746A1 (ru) | Способы и композиции для ингибирования бромодомен-содержащих белков | |
| EA201892008A1 (ru) | Соединения и способы лечения неврологических и сердечно-сосудистых состояний | |
| EA201691141A1 (ru) | Соединения против ccr6 | |
| PH12019501224A1 (en) | Compositions for treatment of polycystic kidney disease | |
| EA202092002A1 (ru) | 5-гетероарилзамещенные индазол-3-карбоксамиды и их получение и применение | |
| MX2018002354A (es) | Métodos para el tratamiento de una enfermedad poliquística renal. | |
| EA201692051A1 (ru) | Арилзамещенные гетероциклилсульфоны | |
| CY1117378T1 (el) | Αναστολεις ινδαζολης toy wnt μονοπατιου μεταγωγης σηματος και θεραπευτικες χρησεις αυτων |